Giuseppe Pulitano

TAMIXAM^® is a novel technology that combines hyaluronic acid and tamarind seed extract in its formulation. It is designed to protect the esophageal mucosa by creating a barrier through its filmogenic properties. The aim of this study is to evaluate the safety and efficacy of this technology through mucoadhesion tests, a cell viability assay, TEER measurements, and morphological analysis on reconstructed esophageal mucosa exposed to 10% hydrochloric acid before and after treatment. The mucoadhesion test highlighted the synergistic bioadhesive effect of the technology’s components. Cell viability assays revealed the substantial mucoprotective and barrier effects of the technology, preserving tissue viability when applied before exposure to acid insult. A morphological analysis illustrated TAMIXAM^®’s efficacy in countering acid-induced damage, reducing erosion, necrosis, and tissue degeneration compared to the positive control, both pre- and post-acid insult. An evaluation of epithelial integrity through TEER measurements indicated a minimal reduction in tissues treated with the invention before acid exposure, demonstrating its ability to maintain epithelial integrity in the presence of an acid insult. However, this effect was less pronounced in tissues treated with the technology after the acid insult, implying a potential partial recovery of epithelial integrity. Furthermore, comprehensive in vitro and in vivo studies supported the safety profile of the invention. In conclusion, TAMIXAM^® emerged as a compelling solution, providing enhanced mechanical action to maintain epithelial balance and shield the esophageal mucosa from acid-induced damage.

Otolaryngological disorders encompass a broad spectrum of conditions that affect the ear, nose, and throat. These conditions often lead to significant discomfort, a reduced quality of life, and the necessity for effective and well-tolerated therapeutic interventions. This article aims to provide an efficacy and safety assessment of VIARINOX^®, a patented technology designed to remove mucus residue from nasal passages in both children and adults, targeting nasal congestion. The study focused on evaluating the antioxidant and anti-inflammatory capacities and the barrier effect of the patented technology. This evaluation involved chemical assays centered on free radical inhibition and assays conducted on reconstructed respiratory epithelium inserts, where damage was induced using LPS. The results obtained indicate that, owing to the presence of sodium hyaluronate, methylsulfonylmethane, and N-acetyl cysteine, this technology could serve as a pharmacological tool for treating otolaryngological disorders and as a preventive measure against the risk of microbial contamination.